Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 1/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16795993 | 0.84 | SMN1; SMN2 (0.40) | KCNN4CTSLKMT2AMAPTMEN1 | |
| SCHEMBL19423364 | 0.84 | KCNN4 (0.34) | KCNN4PLCG1 | |
| SCHEMBL19423359 | 0.84 | KCNN4 (0.34) | KCNN4PLCG1 | |
| SCHEMBL16795999 | 0.84 | KCNN4 (0.34) | KCNN4PLCG1 | |
| SCHEMBL4222858 | 0.80 | KCNN4 (0.58) | KCNN4SRCHDAC3HDAC4HDAC1 | |
| SCHEMBL9978276 | 0.78 | PLCG1 (0.46) | KCNN4HDAC6PLCG1KMT2AMAPT | |
| SCHEMBL18982724 | 0.78 | KDM4E (0.39) | KCNN4PLCG1MAPTKDM4E | |
| SCHEMBL16797695 | 0.76 | AR (0.42) | PLCG1MAPTKDM4E | |
| SCHEMBL16795991 | 0.75 | KCNN4 (0.45) | KCNN4CTSLKMT2AMAPTMEN1 | |
| SCHEMBL19047418 | 0.75 | PLCG1 (0.40) | PLCG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3303342-B1 | IMIDAZO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2021-03-17 | — | — | EP | disclosed |
| EP-3303342-B1 | IMIDAZO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2021-03-17 | — | — | EP | disclosed |
| EP-3079700-B1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2020-11-25 | — | — | EP | disclosed |
| EP-3079700-B1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2020-11-25 | — | — | EP | disclosed |
| US-10245264-B2 | Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2019-04-02 | — | — | US | disclosed |
| US-10245264-B2 | Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20180147208-A1 | IMIDAZO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180147208-A1 | IMIDAZO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-31 | — | — | US | disclosed |
| EP-3303342-A1 | IMIDAZO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | Merck Sharp & Dohme Corp. (US) | 2018-04-11 | — | — | EP | disclosed |
| US-9783552-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9365574-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2016-06-14 | — | — | US | disclosed |
| EP-2575473-B1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2016-01-20 | — | — | EP | disclosed |
| CN-103096718-B | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2016-01-20 | — | — | CN | disclosed |
| WO-2015088886-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015088886-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2015-06-18 | — | — | WO | disclosed |
| CN-103096718-A | Soluble guanylate cyclase activators | MERCK SHARP & DOHME | 2013-05-08 | — | — | CN | disclosed |
| EP-2575473-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | Merck Sharp & Dohme Corp. (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20130072492-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME LLC | 2013-03-21 | — | — | US | disclosed |
| US-20130072492-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME LLC | 2013-03-21 | — | — | US | disclosed |
| WO-2011149921-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180147208-A1 | IMIDAZO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | PDE3A, PRKG1, PDE2A | KCNN4 1861/4885SRC 1005/4885HDAC3 3175/4885 |
| US-20130072492-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1A2, GUCY1A1, PDE2A | KCNN4 1887/4885SRC 1595/4885HDAC3 4312/4885 |
| US-10245264-B2 | Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators | GUCY1A1, GUCY1A2, PDE2A | KCNN4 1867/4885SRC 1224/4885HDAC3 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.